Objective: To describe the frequency and trends in the use of antipsychotics for adults with schizophrenia in Canada from 2005 to 2009.
A ntipsychotics, since their introduction to clinical medicine 60 years ago, have revolutionized the treatment of schizophrenia, and provided real benefits and hope to patients suffering from this devastating disorder. The quest for the ideal antipsychotic, one that provides remission of both positive and negative symptoms of schizophrenia without disabling side effects, led to the creation of SGAs. Clozapine, the first and only SGA for several decades, was hampered by hematological toxicity and the need for routine monitoring. In the 1990s, risperidone, olanzapine, and quetiapine were introduced for the treatment of schizophrenia. With lower rates of extrapyramidal side effects, a frequent and disabling symptom associated with FGA use, these medications gained widespread use during a relatively short time period. However, over time, the development of significant metabolic side effects related to SGA use became apparent, leading to concerns about the cardiovascular health of patients with schizophrenia. 1 In the last 5 years, 2 large independent trials in the United Kingdom (CUtLASS) 2 and North America (CATIE) 3 compared the effectiveness of FGAs and SGAs in the treatment of schizophrenia in real-world settings. Both trials found FGAs and SGAs to be similarly effective in the treatment of schizophrenia, with the exception of treatment-resistant populations, in which clozapine exhibited superiority. The objective of our study was to describe the frequency and trends in recommendations for antipsychotics for adults with schizophrenia in Canada from 2005 to 2009. We hypothesized that the significant metabolic side effects related to SGA use, and recent evidence from the CUtLASS and CATIE trials, would have an impact on Canadian physicians prescribing behaviours for their patients with schizophrenia.
Methods
IMS Brogan is a proprietary source of pharmacoepidemiologic data. The IMS databases are the only national source for population-based data on antipsychotics for patients with schizophrenia. Administrative data cannot be used for this purpose because, in most Canadian provinces, administrative records for prescription data are only collected in special population groups, for example, those covered by publicly funded drug plans, and the extent of coverage differs across provinces. Several national surveys have collected information on medication use (for example, the National Population Health Survey), but no surveys having an adequate sample size have targeted this specific group.
We performed analyses based on the IMS Brogan CDTI, a national physician panel study. Participating physicians comprise a representative sample, both geographically and by specialty, with weighting adjustments made to estimate national drug recommendations by year. Each physician participating in the panel completes a record of all patient visits during a 2-day period. The nature of each visit, including the age and sex of the patient, drug recommendation, and the therapeutic indication are recorded. Analyses of the CDTI database allow us to characterize the frequency with which physicians recommend antipsychotics for adults with schizophrenia. We also classified perphenazine as a medium-potency agent because its intermediate potency was the basis for its inclusion in the CATIE trial. 5 In keeping with convention, chlorpromazine, thioridazine, and methotrimeprazine were classified as low-potency agents. 6 
Results
Analysis of data from the CDTI showed that FGA drug recommendations for adults with schizophrenia increased by 38% between 2005 and 2009, from 329 380 to 454 960 recommendations. Increases occurred in high-, medium-, and low-potency agents (Figure 1 ). There were notable increases in drug recommendations for chlorpromazine (56%), loxapine (302%), zuclopenthixol (190%), and flupentixol (113%) ( Table 1) 
Discussion
After years of increasing SGA use for the treatment of schizophrenia, it appears that the rate of increase of FGA use is now greater than that of SGAs. Several factors may be contributing to this change in physician prescribing patterns. We suspect, but cannot confirm, that the change may be due in part to dissemination of the results of the CUtLASS and CATIE trials.
Two of the FGAs with the largest increases during the past 5 years were flupentixol and zuclopenthixol, both of which are administered in depot form. Owing to problems with treatment adherence in patients with schizophrenia, the use of depot medications has been favoured in this patient population as a method of ensuring compliance. While evidence has generally supported the superiority of the longacting injections, compared with oral medications (see recent meta-analysis by Leucht et al 7 )
, a recent trial comparing depot risperidone to a clinician-chosen oral antipsychotic failed to find evidence of superiority. 8 Concerns about side effects and tolerability of these preparations have hampered the use of depot antipsychotics. 9 The introduction of the SGAs, with claims of better tolerance and adherence, may have prompted psychiatrists to move away from firstgeneration depot preparations. Community treatment orders and the legal framework by which people in the community with schizophrenia are compelled to accept treatment, may theoretically be associated with higher rates of depot medication use, but there is no evidence that this is true in Canada.
The decreasing use of olanzapine in this patient population may be due to metabolic adverse effects related to its use, the Food and Drug Administration and Health Canada warnings regarding the risk of type II diabetes, and class action law suits against the makers of olanzapine. In 2010, Eli Lilly Canada was ordered by the Ontario, Quebec, and British Columbia courts to pay a sum of about $17 750 000 to people who took Zyprexa before June 6, 2007, and suffered an injury including diabetes, hyperglycemia, ketoacidosis, or pancreatitis.
The increased use of clozapine is likely attributable to emerging data on its superiority in patients who are treatment resistant. In the CUtLASS 2 trial, 10 patients who were treatment resistant to at least 2 previous antipsychotics were randomized to receive either clozapine or a nonclozapine SGA (amisulpiride, olanzapine, quetiapine, risperidone, or zotapine). This trial found a significant benefit for clozapine-treated patients, compared with the other SGAs, in the total Positive and Negative Symptom Scale score, and greater improvement in mental health on patient satisfaction questionnaires.
Limitations of our study include the possibility of sampling errors with the CDTI database, which may over-or underestimate national drug recommendations. The drug recommendation estimates neither provide a measure of the number of prescriptions filled nor the degree of compliance with therapy. The reasons for changes in antipsychotic prescriptions can only be hypothesized and not confirmed. Other factors, such as changes in the frequency with which physicians write and refill prescriptions, could also contribute to the alterations seen in drug recommendations during the past 5 years.
Conclusions
Increasing use of FGAs for the treatment of schizophrenia appears to be starting in Canada. Accumulating clinical trial and pharmacoepidemiologic data may be guiding a more informed, nuanced, and evidence-based pattern of use of these medications. However, it should be emphasized that the data presented here are descriptive. Our study could not assess explanations for the trends observed. 
Conclusion :
Le taux d'augmentation de l'utilisation d'APG est désormais supérieur à celui des ADG. Cela peut être causé par de récents essais comparatifs, qui suggèrent que l'efficacité clinique ainsi que le taux des effets secondaires neurologiques sont semblables entre les APG et les ADG. L'utilisation décroissante de l'olanzapine peut s'expliquer par les effets métaboliques indésirables. L'utilisation croissante de la clozapine peut être attribuable aux données sur sa supériorité chez les patients réfractaires au traitement.
